Chronic Heart Failure

Cardiovascular
7
Pipeline Programs
10
Companies
19
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 17 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
Iron protein succinylate oral solutionPhase 41 trial
Active Trials
NCT03344523Unknown600Est. Dec 2019
Verona Pharma
Verona PharmaUK - London
1 program
1
allopurinolPhase 41 trial
Active Trials
NCT00477789Completed
DS
Daiichi SankyoChina - Shanghai
1 program
1
olmesartan medoxomil + candesartan cilexetil placeboPhase 31 trial
Active Trials
NCT00679484Terminated400Est. Nov 2009
Akros Pharma
Akros PharmaNJ - Princeton
1 program
1
JTT-861 CapsulesPhase 21 trial
Active Trials
NCT06017609Active Not Recruiting314Est. Dec 2026
Sanofi
SanofiPARIS, France
1 program
1
Vasopressin V2 Receptor AntagonistPhase 21 trial
Active Trials
NCT00032747Completed338Est. Feb 2003
Abbott
AbbottABBOTT PARK, IL
2 programs
1
EnligHTN™ Renal Denervation SystemPhase 1/22 trials
CRTN/A1 trial
Active Trials
NCT02367716Completed121Est. Mar 2017
NCT02471729Unknown12Est. Jan 2018
NCT01911078Completed20Est. Jun 2016
Moderna
ModernaCAMBRIDGE, MA
1 program
1
mRNA-0184Phase 1RNA Therapeutic1 trial
Active Trials
NCT05659264Completed48Est. Dec 2024
Rhythm Pharmaceuticals
7 programs
HeartWare Ventricular Assist DeviceN/A1 trial
HeartWare Ventricular Assist DeviceN/A1 trial
HeartWare Ventricular Assist DeviceN/A1 trial
HeartWare® VASN/A1 trial
HeartWare® VASN/A1 trial
+2 more programs
Active Trials
NCT03681210Active Not Recruiting300Est. Apr 2026
NCT04065997Terminated147Est. Jul 2021
NCT03697980Completed136Est. Feb 2022
+4 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
EplerenoneN/A1 trial
observationN/A1 trial
Active Trials
NCT03342690Completed1,165Est. Jul 2020
NCT02790801Completed1,000Est. May 2017
Novartis
NovartisBASEL, Switzerland
1 program
EntrestoN/A1 trial
Active Trials
NCT04781881Completed688Est. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lee's PharmaceuticalIron protein succinylate oral solution
Daiichi Sankyoolmesartan medoxomil + candesartan cilexetil placebo
Akros PharmaJTT-861 Capsules
SanofiVasopressin V2 Receptor Antagonist
AbbottEnligHTN™ Renal Denervation System
ModernamRNA-0184
Rhythm PharmaceuticalsMedtronic HeartWare ™ HVAD™ System
NovartisEntresto
Rhythm PharmaceuticalsHeartWare Ventricular Assist Device
Rhythm PharmaceuticalsHeartWare Ventricular Assist Device
Rhythm PharmaceuticalsHeartWare Ventricular Assist Device
PfizerEplerenone
Pfizerobservation
AbbottCRT
AbbottEnligHTN™ Renal Denervation System

Showing 15 of 18 trials with date data

Clinical Trials (19)

Total enrollment: 6,374 patients across 19 trials

NCT00477789Verona Pharmaallopurinol

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

Phase 4Completed
NCT03344523Lee's PharmaceuticalIron protein succinylate oral solution

Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency

Start: Jan 2018Est. completion: Dec 2019600 patients
Phase 4Unknown
NCT00679484Daiichi Sankyoolmesartan medoxomil + candesartan cilexetil placebo

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24

Start: Jun 2008Est. completion: Nov 2009400 patients
Phase 3Terminated
NCT06017609Akros PharmaJTT-861 Capsules

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

Start: Dec 2023Est. completion: Dec 2026314 patients
Phase 2Active Not Recruiting
NCT00032747SanofiVasopressin V2 Receptor Antagonist

Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

Start: Aug 2001Est. completion: Feb 2003338 patients
Phase 2Completed
NCT02471729AbbottEnligHTN™ Renal Denervation System

Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque

Start: Jan 2017Est. completion: Jan 201812 patients
Phase 1/2Unknown
NCT05659264ModernamRNA-0184

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Start: Dec 2022Est. completion: Dec 202448 patients
Phase 1Completed
NCT04854200Rhythm PharmaceuticalsMedtronic HeartWare ™ HVAD™ System

HVAD(TM) SMART 1.0 Study

Start: May 2021Est. completion: Aug 20250
N/AWithdrawn
NCT04781881NovartisEntresto

Special Drug Use Surveillance for Entresto Tablets

Start: Mar 2021Est. completion: Apr 2023688 patients
N/ACompleted
NCT04065997Rhythm PharmaceuticalsHeartWare Ventricular Assist Device

Apogee International

Start: Sep 2019Est. completion: Jul 2021147 patients
N/ATerminated
NCT03697980Rhythm PharmaceuticalsHeartWare Ventricular Assist Device

Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

Start: Jan 2019Est. completion: Feb 2022136 patients
N/ACompleted
NCT03681210Rhythm PharmaceuticalsHeartWare Ventricular Assist Device

Destination Therapy Post Approval Study

Start: Oct 2018Est. completion: Apr 2026300 patients
N/AActive Not Recruiting
NCT03342690PfizerEplerenone

Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

Start: Jul 2017Est. completion: Jul 20201,165 patients
N/ACompleted
NCT02790801Pfizerobservation

The First Russian Observational Survey of Heart Failure Patients With Atrial Fibrillation

Start: Feb 2015Est. completion: May 20171,000 patients
N/ACompleted
NCT02367716AbbottCRT

Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure

Start: Dec 2014Est. completion: Mar 2017121 patients
N/ACompleted
NCT01911078AbbottEnligHTN™ Renal Denervation System

Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)

Start: Sep 2014Est. completion: Jun 201620 patients
N/ACompleted
NCT01966458Rhythm PharmaceuticalsHeartWare® VAS

A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)

Start: Oct 2013Est. completion: Aug 2020494 patients
N/ACompleted
NCT01166347Rhythm PharmaceuticalsHeartWare® VAS

The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial

Start: Aug 2010Est. completion: May 2017451 patients
N/ACompleted
NCT00751972Rhythm PharmaceuticalsHeartWare® VAS

Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

Start: Aug 2008Est. completion: Aug 2013140 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)